Denosumab, a monoclonal antibody targeting RANKL, has emerged as a highly effective agent for reducing osteoclast-mediated bone resorption and controlling hypercalcemia in this population [2,8]. This evidence concerns the gene TNFSF11 and hypercalcemia disease.